The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I study to assess the safety, tolerability, and PK of dovitinib (D) in combination with gemcitabine (G) and capecitabine (C) in patients with advanced solid tumors.
Gerald J. Fetterly
No relevant relationships to disclose
Laura Pitzonka
No relevant relationships to disclose
Yujie Zhao
No relevant relationships to disclose
Grace K. Dy
No relevant relationships to disclose
Renuka V. Iyer
No relevant relationships to disclose
Susan Taubes
No relevant relationships to disclose
Jose Ricardo Perez
No relevant relationships to disclose
Kenneth W. Culver
No relevant relationships to disclose
John Wilton
No relevant relationships to disclose
Krystin Mongiardo
No relevant relationships to disclose
Wei Tan
No relevant relationships to disclose
William E. Brady
No relevant relationships to disclose
Amy Whitworth
No relevant relationships to disclose
Alex A. Adjei
No relevant relationships to disclose
Wen Wee Ma
No relevant relationships to disclose